Helix BioPharma Corp. (TSX:HBP, OTC PINK:HBPCD, FRANKFURT:HBP0) announced the appointments of Helen Middleton as General Counsel and David Browning as Vice President of Clinical Operations, strengthening its executive leadership team as the company prepares for a planned U.S. securities exchange listing and advances its lead candidate L-DOS47 into the next stage of clinical development.
According to the company, the appointments are part of a deliberate effort to build the legal, governance, and operational infrastructure needed to support Helix's next phase of growth. Thomas Mehrling, MD, PhD, Chief Executive Officer, stated, "The next stage of Helix's evolution demands a different kind of company than the one we were building two years ago. As we prepare for our planned U.S. securities exchange listing and advance L-DOS47 into its next stage of clinical development, we are deliberately strengthening every part of the organization."
Helix is currently preparing a base shelf prospectus and has completed auditor review of its second-quarter financials, executing on a capital markets roadmap ahead of the planned U.S. listing. The company is also advancing L-DOS47 through LDOS007, a planned Phase IB/Randomized Phase II study in first-line non-small cell lung cancer (NSCLC).
Helen Middleton brings more than 30 years of experience as a qualified life sciences lawyer and registered clinical pharmacist. Her career includes senior legal roles at Sidley Austin LLP, Matheson LLP, Mundipharma International, Ipsen, and Abcam, and most recently as Legal Consultant to Kyowa Kirin International. As General Counsel, she will oversee legal affairs, governance, compliance, and strategic transactions.
David Browning brings more than 30 years of experience leading global clinical development programs across biotechnology, pharmaceutical, and academic sectors. He has overseen more than 30 Phase I-III clinical studies spanning first-in-human through regulatory approval, with expertise in oncology indications including immunotherapies, targeted therapies, and antibody-drug conjugates. As Vice President of Clinical Operations, he will lead operational planning and execution of Helix's clinical programs, including LDOS007.
Helix BioPharma is an oncology company focused on near-term solutions for hard-to-treat cancers. Its pipeline includes L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. The company also advances pre-IND candidates LEUMUNA, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA, an oral gemcitabine prodrug. For more information, visit https://www.helixbiopharma.com/.
